Lesions involving more than 25% of the lung were more frequent in post-COVID-19 residual abnormalities than in fibrotic and non-fibrotic ILA (30% vs. 0% and 5%, respectively; p = 0.03). The gene discussed is TNFRSF9; the disease is COVID-19.